'achalasia'' and ''motility disorder esophagus''
Conditions
Interventions
Daily 20 mg of citalopram or a placebo for a period of 6 weeks.
Sponsors
Academisch Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Written informed consent Minimum age: 18 years Diagnosed with achalasia type 1 or 2 Previously treated with pneumodilatation, Heller*s myotomy or POEM >=3 months post-treatment for achalasia Recurrent chest pain
Exclusion criteria
Exclusion criteria: Achalasia type 3 (**spastic type**) Surgery of the esophagus (except Heller*s myotomy and POEM) Currently using antidepressants Chest pain suspect of cardiac origin. Severe and clinically unstable concomitant disease (e.g. liver, cardiovascular or lung disease, neurological or psychiatric disorders, cancer or AIDS and other endocrine disorders) Medication-related (contra-indications for citalopram)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| • Global assessment of chest pain after 6 weeks of treatment with citalopram. | — |
Secondary
| Measure | Time frame |
|---|---|
| • Symptom frequency and symptom severity score (calculated from symptom diary) • Health-related Quality of life (SF-36) • Achalasia-specific health-related quality of life (Ach-HRQL) • Hospital Anxiety and depression scale (HADS) • Symptom severity and time to perception during esophageal acid perfusion and during esophageal barostat balloon distension test (sub-study). • Adverse events/ complications/ side-effects | — |
Countries
Netherlands
Outcome results
None listed